Augusto Ocana

81 year

Health Technology

Profile

Augusto Ocana was a Director at CytoCore, Inc. He was also a Director, General Manager & Senior Vice President at C.H.
Werfen, Inc. from 1999 to 2006.
From 2006 to 2018, he was a Director at MEDITE Cancer Diagnostics, Inc.

Former positions of Augusto Ocana

Companies	Position	End
MEDITE CANCER DIAGNOSTICS INC	Director/Board Member	2018-01-22
C.H. Werfen, Inc.	Director/Board Member	2005-12-31
CytoCore, Inc. CytoCore, Inc. Medical SpecialtiesHealth Technology CytoCore, Inc. develops, manufactures and sells an integrated family of products for the detection, diagnosis and treatment of cancer. The company markets its products under the trade name CytoCore Solutions, which is intended to address sample collection, specimen preparation, specimen evaluation, including detection/screening and diagnosis, treatment and patient monitoring within vertical markets related to specific cancers. The company also designs, markets and sells a companion product to detect breast cancer. It intends to focus on the expansion of its products for the treatment of gynecological cancer as well as bladder, lung, and breast cancers amongst others. CytoCore was founded in December 1998 and is headquartered in Chicago, IL.	Director/Board Member	-

See the detail of Augusto Ocana's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Augusto Ocana's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
MEDITE CANCER DIAGNOSTICS INC	Health Technology

Private companies	2
CytoCore, Inc. CytoCore, Inc. Medical SpecialtiesHealth Technology CytoCore, Inc. develops, manufactures and sells an integrated family of products for the detection, diagnosis and treatment of cancer. The company markets its products under the trade name CytoCore Solutions, which is intended to address sample collection, specimen preparation, specimen evaluation, including detection/screening and diagnosis, treatment and patient monitoring within vertical markets related to specific cancers. The company also designs, markets and sells a companion product to detect breast cancer. It intends to focus on the expansion of its products for the treatment of gynecological cancer as well as bladder, lung, and breast cancers amongst others. CytoCore was founded in December 1998 and is headquartered in Chicago, IL.	Health Technology
C.H. Werfen, Inc.